Heparin

Summary

Heparin (CHEMBL4650299) is an approved oligosaccharide (ATC S01XA14) targeting SERPINC1; indicated across 59 conditions including eye disorder and varicose disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• ATC class: S01XA14 (+2 more)
• Targets: 1 (SERPINC1)
• Indications: 59 conditions
• Clinical trials: 312

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650299
Name	Heparin
Type	Oligosaccharide
Max phase	4
ATC	S01XA14, B01AB01, C05BA03

Also known as: B01AB10, Heparin, Heparin porcine, Heparin porcine intestinal mucosa, porcine, heparin, HEPARIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SERPINC1	serpin family C member 1	Activation	7.85	0%	P01008
	CoV Spike glycoprotein	Binding	9

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SERPINC1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SERPINC1
R-HSA-140837	1	SERPINC1
R-HSA-140875	1	SERPINC1
R-HSA-140877	1	SERPINC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	SERPINC1
Metabolism of proteins	1	SERPINC1
Post-translational protein modification	1	SERPINC1
Post-translational protein phosphorylation	1	SERPINC1
Fibrin formation	1	SERPINC1
Initiation of coagulation cascade	1	SERPINC1
Regulation of clotting cascade	1	SERPINC1
Amplification and propagation of coagulation cascade	1	SERPINC1

Dominant GO biological processes

GO term	Targets
blood coagulation	1
regulation of blood coagulation	1
hemostasis	1

Indications & clinical

Indications

59 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0003966
varicose disease	4	MONDO:0008638	HP:0002619
thrombotic disease	4	MONDO:0000831	HP:0004419
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
aortic valve stenosis	3	MONDO:0042981	EFO:0000266
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
fetal growth restriction	3	MONDO:0005030	EFO:0000495
injury	3	MONDO:0021178	EFO:0000546
myocardial infarction	3	MONDO:0005068	EFO:0000612
neoplasm	3	MONDO:0005070	EFO:0000616
stroke disorder	3	MONDO:0005098	EFO:0000712
subarachnoid hemorrhage	3	MONDO:0005099	EFO:0000713
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
coronary artery disorder	3	MONDO:0005010	EFO:0001645
pneumonia	3	MONDO:0005249	EFO:0003106
heart disorder	3	MONDO:0005267	EFO:0003777
pulmonary embolism	3	MONDO:0005279	EFO:0003827
chronic kidney disease	3	MONDO:0005300	EFO:0003884
venous thromboembolism	3	MONDO:0005399	EFO:0004286
acute lung injury	3	MONDO:0015796	EFO:0004610
acute coronary syndrome	3	MONDO:0005542	EFO:0005672
acute myocardial infarction	3	MONDO:0004781	EFO:0008583
ST-elevation myocardial infarction	3	MONDO:0041656	EFO:0008585
proliferative vitreoretinopathy	3	MONDO:0700115	EFO:1001129
myocardial ischemia	3	MONDO:0024644	EFO:1001375
kidney failure	3	MONDO:0001106	EFO:1002048
female reproductive system neoplasm	3	MONDO:0021148	MONDO:0021148
atrial fibrillation	2	MONDO:0004981	EFO:0000275
infertility disorder	2	MONDO:0005047	EFO:0000545
preeclampsia	2	MONDO:0005081	EFO:0000668
bacterial infectious disease with sepsis	2	MONDO:0005229	EFO:0003033
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
interstitial cystitis	2	MONDO:0018301	EFO:0008507
burn	2	MONDO:0043519	EFO:0009516
intermediate coronary syndrome	2	MONDO:0006805	EFO:1000985
hemorrhagic disease	2	MONDO:0002243	MONDO:0002243
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
obesity disorder	1	MONDO:0011122	EFO:0001073
urinary tract infection	1	MONDO:0100338	EFO:0003103
acute respiratory distress syndrome	1	MONDO:0006502	EFO:1000637
stomatitis	1	MONDO:0004842	EFO:1001904
thrombophlebitis	1	MONDO:0002800	HP:0004418

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 312.

Phase distribution

Phase	Trials
PHASE4	81
Not specified	80
PHASE3	73
PHASE2	35
PHASE1	16
PHASE2/PHASE3	15
PHASE1/PHASE2	7
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04496362	PHASE4	ACTIVE_NOT_RECRUITING	Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
NCT04725201	PHASE4	RECRUITING	Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
NCT05984537	PHASE4	RECRUITING	A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
NCT06375616	PHASE4	NOT_YET_RECRUITING	Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
NCT06442267	PHASE4	RECRUITING	Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
NCT07404345	PHASE4	NOT_YET_RECRUITING	Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)
NCT07609771	PHASE4	NOT_YET_RECRUITING	Heparin to Prevent Organ Failure in Acute Pancreatitis
NCT00049777	PHASE4	COMPLETED	A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
NCT00188773	PHASE4	COMPLETED	Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion
NCT00196469	PHASE4	UNKNOWN	Impact of Heparin on the Need for Mechanical Ventilation in Neonates
NCT00253396	PHASE4	COMPLETED	Patients Preference With Self-Injection: The PRISM Study
NCT00253851	PHASE4	COMPLETED	Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery
NCT00262054	PHASE4	COMPLETED	Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
NCT00277394	PHASE4	COMPLETED	Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
NCT00373451	PHASE4	COMPLETED	Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
NCT00407641	PHASE4	WITHDRAWN	Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis
NCT00435487	PHASE4	TERMINATED	Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
NCT00439855	PHASE4	COMPLETED	Enoxaparin Versus Unfractionated Heparin in PCI
NCT00445328	PHASE4	TERMINATED	Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
NCT00448461	PHASE4	COMPLETED	Antithrombotic Regimens and Outcome
NCT00571259	PHASE4	COMPLETED	Prophylactic Antimicrobial Catheter Lock
NCT00669149	PHASE4	TERMINATED	Anticoagulant Treatments and Percutaneous Coronary Angioplasty
NCT00735280	PHASE4	COMPLETED	Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI
NCT00790387	PHASE4	COMPLETED	Tirofiban and Enoxaparin in High Risk Coronary Intervention
NCT00890214	PHASE4	COMPLETED	Prostacyclin’s Effect on Platelet Responsiveness
NCT00976092	PHASE4	UNKNOWN	Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
NCT01084993	PHASE4	UNKNOWN	EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding
NCT01214772	PHASE4	COMPLETED	The Effect of Heparin in Treatment IVF-ET Failure
NCT01228292	PHASE4	UNKNOWN	Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.
NCT01267487	PHASE4	COMPLETED	Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass
NCT01343381	PHASE4	COMPLETED	Comparison of Heparin Types; Efficacy and Safety
NCT01464671	PHASE4	TERMINATED	Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
NCT01519518	PHASE4	COMPLETED	How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
NCT01634438	PHASE4	COMPLETED	Heparin Dose for Radial Angiography
NCT01694459	PHASE4	UNKNOWN	DEDICA (Dose of HEparin During Coronary Angioplasty) Trial
NCT01696110	PHASE4	COMPLETED	BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.
NCT01794767	PHASE4	SUSPENDED	Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children
NCT01823393	PHASE4	TERMINATED	Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure
NCT01862978	PHASE4	UNKNOWN	Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke
NCT01917799	PHASE4	UNKNOWN	Aspirin, Heparin and Miscarriage

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
IDRAPARINUX	ChEMBL	Phase 3	SERPINC1
fondaparinux	PubChem	Approved	SERPINC1